Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Monashee Investment Management LLC

Q4 2023 · 13F-HR

Monashee Investment Management LLCholdings as filed

Filed 2024-02-12 · accession 0001172661-24-000711

$566.5M
Reported value
44
Positions
2023-12-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
464287200IVVISHARES TR$118.8M21.0%248,710CommonSOLE
922908363VOOVANGUARD INDEX FDS$118.4M20.9%271,010CommonSOLE
921943858VEAVANGUARD TAX-MANAGED FDS$74.2M13.1%1,549,700CommonSOLE
46432F842IEFAISHARES TR$55.0M9.72%782,380CommonSOLE
922042858VWOVANGUARD INTL EQUITY INDEX F$38.8M6.84%942,960CommonSOLE
46434G103IEMGISHARES INC$33.4M5.90%660,700CommonSOLE
464287150ITOTISHARES TR$22.8M4.03%216,860CommonSOLE
922908769VTIVANGUARD INDEX FDS$22.8M4.02%96,060CommonSOLE
86366E106GPCRSTRUCTURE THERAPEUTICS INC$7.8M1.38%191,855CommonSOLE
N00985106AERAERCAP HOLDINGS NV$6.7M1.18%90,000CommonSOLE
69331C108PCGPG&E CORP$4.7M0.83%260,000CommonSOLE
500946108KRROKORRO BIO INC$4.4M0.77%90,805CommonSOLE
30233G209EYPTEYEPOINT PHARMACEUTICALS INC$4.0M0.71%175,000CommonSOLE
15117B202CLDXCELLDEX THERAPEUTICS INC NEW$4.0M0.70%100,209CommonSOLE
G76279101ROIVROIVANT SCIENCES LTD$3.9M0.69%350,000CommonSOLE
04016X101ARGXARGENX SE$3.8M0.67%10,000CommonSOLE
517834107LVSLAS VEGAS SANDS CORP$3.7M0.65%75,000CommonSOLE
38341P102GOSSGOSSAMER BIO INC$3.2M0.56%3,459,854CommonSOLE
641871108AMBRX BIOPHARMA INC$3.0M0.52%207,500CommonSOLE
45258J102IMVTIMMUNOVANT INC$2.9M0.52%70,000CommonSOLE
85205L107SWTXUSDSPRINGWORKS THERAPEUTICS INC$2.7M0.48%73,949CommonSOLE
71424F105PRPERMIAN RESOURCES CORP$2.4M0.42%175,900CommonSOLE
34379V103FLNCFLUENCE ENERGY INC$2.4M0.42%100,000CommonSOLE
92243G108PCVXVAXCYTE INC$2.4M0.42%37,500CommonSOLE
92540K109VTMXVESTA REAL ESTATE CORP$2.2M0.38%55,000CommonSOLE
02215L209KNTKKINETIK HOLDINGS INC$2.2M0.38%64,900CommonSOLE
49845K101KVYOKLAVIYO INC$1.9M0.34%68,974CommonSOLE
05153U107AURAAURA BIOSCIENCES INC$1.8M0.31%198,415CommonSOLE
40416E103HCIHCI GROUP INC$1.7M0.31%19,790CommonSOLE
21871X109CRBGCOREBRIDGE FINL INC$1.6M0.29%75,000CommonSOLE
282559103ETNBGBP89BIO INC$1.6M0.28%140,000CommonSOLE
78163D100RWAYRUNWAY GROWTH FINANCE CORP$1.2M0.20%91,739CommonSOLE
02083G100NVLSEURALPINE IMMUNE SCIENCES INC$964,1030.17%74,792CommonSOLE
62855J104MYGNMYRIAD GENETICS INC$957,0000.17%50,000CommonSOLE
20454B104CMPXCOMPASS THERAPEUTICS INC$780,0000.14%500,000CommonSOLE
82024L103STTKSHATTUCK LABS INC$713,0000.13%100,000CommonSOLE
037326105ANTXAN2 THERAPEUTICS INC$696,5990.12%33,997CommonSOLE
09609G100BLUEBIRD BIO INC$690,0000.12%500,000CommonSOLE
Y95308105WVEWAVE LIFE SCIENCES LTD$521,6650.09%103,300CommonSOLE
608550208MTEMEURMOLECULAR TEMPLATES INC$454,4670.08%121,841CommonSOLE
171757107CIDARA THERAPEUTICS INC$293,0650.05%369,099CommonSOLE
92854T100VIVID SEATS INC$189,6000.03%30,000CommonSOLE
74623V103PCTPURECYCLE TECHNOLOGIES INC$47,6040.01%11,754CommonSOLE
48576U106KPTIEURKARYOPHARM THERAPEUTICS INC$34,9230.01%132,435CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.